Abstract:Abstract Drug-coated balloons have proved to be an effective technology in percutaneous transluminal angioplasty in treating peripheral artery disease. Paclitaxel-based coating is mainly used. Solutions to such problems as drug loss and inefficient drug release during operations, however, have not been found yet. This study aims to explore the activity of a newly designed paclitaxel-coated balloon in vitro using pectin as the excipient (pectin-paclitaxel) compared with the commercially available shellac excipient balloon, and to characterize the novel nanoparticle paclitaxel-coated balloon with peptide (Arg-Gly-Asp-Ser, RGDS) derivative RGDS-OC 8 H 17 (pectin-RGDS-OC8H17-paclitaxel). Two coating solutions, pectin-paclitaxel and pectin-RGDS-OC 8 H 17 -paclitaxel, were successively designed and prepared. The morphology of both coating solutions was first characterized compared with the control group, the commercially available paclitaxel-coated balloon. Then the in vitro experiments were conducted to determine the drug-releasing profiles of both pectin-paclitaxel and pectin-RGDS-OC 8 H 17 -paclitaxel coatings. The pectin-RGDS-OC 8 H 17 -paclitaxel-coated balloon was smoother and more homogeneous compared with the commercially available paclitaxel-coated balloon and the pectin-paclitaxel-coated balloon. This difference was more obvious when paclitaxel was at low concentration. During the in vitro trial, the drug-releasing curve of the pectin-RGDS-OC8H17-paclitaxel model showed an adjustable paclitaxel-releasing: more than 90% of the paclitaxel released in 2 h at 300 rpm and more than 99% released in 10 min at 1200 rpm. C ompared to the performance of the current commercially available shellac excipient products and the pectin-paclitaxel coating, pectin-RGDS-OC 8 H 17 -paclitaxel coating provided higher drug-releasing speed. However, the clinical outcomes of this finding need to be further demonstrated. Paclitaxel-coated balloons as an effective therapeutic strategy currently in treating peripheral arterial disease need to be further improved in terms of its efficiency in anti-proliferative drug delivery and release. The pectin-RGDS-OC 8 H 17 -paclitaxel coating solution developed in this study exhibited excellent drug-releasing properties. Further experiments are still needed to demonstrate the performance of this novel drug-coated balloon in vivo and its clinical importance.

In Vitro and In Vivo Comparative Evaluation of a Shellac-Ammonium Paclitaxel-Coated Balloon versus a Benchmark Device

Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis

Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis: The RESTORE ISR China Randomized Trial.

Comparison of Drug-Coated Balloon and Drug-Eluting Stent for the Treatment of Small Vessel Disease (from the Dissolve SVD Randomized Trial).

A Randomized Comparison of Two Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis: the LONGTY ISR China Randomized Trial (LONGTY DCB Vs. SeQuent Please DCB).

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

A Randomized Comparison of 2 Different Drug-Coated Balloons for In-Stent Restenosis

TCT-273 Randomized Comparison of Two Different Drug-Coated Balloons in In-Stent Restenosis: the PROPAX Trial

Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy

Comparison of the Safety and Efficacy of Two Types of Drug-Eluting Balloons (RESTORE DEB and SeQuent® Please) in the Treatment of Coronary In-Stent Restenosis: Study Protocol for a Randomized Controlled Trial (RESTORE ISR China).

In vitro evaluation of nanoparticle drug-coated balloons: a pectin-RGDS-OC8H17-paclitaxel solution

Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease

Biolimus-Coated Balloon in Small-Vessel Coronary Artery Disease the BIO-RISE CHINA Study

Drug‐coated Balloon for the Treatment of Small Vessel Disease: 9 Months of Angiographic Results and 12 Months of Clinical Outcomes of the PEPCAD China SVD Study

Drug-Coated Balloons: Drugs Beyond Paclitaxel?

Ultrasound controlled paclitaxel releasing system—A novel method for improving the availability of coronary artery drug coated balloon

A Randomized Comparison of a Novel Iopromide-Based Paclitaxel-Coated Balloon Shenqi Versus SeQuent Please for the Treatment of In-Stent Restenosis.

Comparative long‐term efficacy and safety of two paclitaxel‐coated balloons with different coating strategies for the treatment of drug‐eluting coronary stent restenosis

Comparative Evaluation of Local and Downstream Responses in Two Commercially Available Paclitaxel-Coated Balloons in Healthy Peripheral Arteries of a Swine Model

A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions

Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients